Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications

ABSTRACT Background Inactivating BRCA1/2 mutations confer sensitivity to poly(ADP‐ribose) polymerase inhibitors (PARPi) in prostate cancer (PCA). However, secondary BRCA1/2 reversion mutations (BRCArev) can restore BRCA function and mediate acquired PARPi resistance. While BRCArev typically arise un...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Douglas I. Lin, Elizabeth Lawrence, Natalie Danziger, Huihui Ye, Brennan Decker, Ole Gjoerup, Ryon P. Graf, Jeffrey S. Ross, Richard S. P. Huang, Julia A. Elvin, Douglas A. Mata, Rana R. McKay
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-01-01
Edice:	Cancer Medicine
Témata:	BRCA1/2 liquid biopsy PARP inhibitor prostate cancer reversion
On-line přístup:	https://doi.org/10.1002/cam4.71489
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!